Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination.


Journal

Nature nanotechnology
ISSN: 1748-3395
Titre abrégé: Nat Nanotechnol
Pays: England
ID NLM: 101283273

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 19 12 2022
accepted: 18 01 2024
medline: 16 3 2024
pubmed: 16 3 2024
entrez: 16 3 2024
Statut: aheadofprint

Résumé

Multivalent presentation of ligands often enhances receptor activation and downstream signalling. DNA origami offers a precise nanoscale spacing of ligands, a potentially useful feature for therapeutic nanoparticles. Here we use a square-block DNA origami platform to explore the importance of the spacing of CpG oligonucleotides. CpG engages Toll-like receptors and therefore acts to activate dendritic cells. Through in vitro cell culture studies and in vivo tumour treatment models, we demonstrate that square blocks induce Th1 immune polarization when CpG is spaced at 3.5 nm. We observe that this DNA origami vaccine enhances DC activation, antigen cross-presentation, CD8 T-cell activation, Th1-polarized CD4 activation and natural-killer-cell activation. The vaccine also effectively synergizes with anti-PD-L1 for improved cancer immunotherapy in melanoma and lymphoma models and induces long-term T-cell memory. Our results suggest that DNA origami may serve as a platform for controlling adjuvant spacing and co-delivering antigens in vaccines.

Identifiants

pubmed: 38491184
doi: 10.1038/s41565-024-01615-3
pii: 10.1038/s41565-024-01615-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : CA244726-01
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : CA244726-01
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : CA244726-01

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355–1360 (2018).
pubmed: 29567706 doi: 10.1126/science.aar7112
Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98, 9237–9242 (2001).
pubmed: 11470918 pmcid: 55404 doi: 10.1073/pnas.161293498
Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. & Klinman, D. M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10, 499–511 (2011).
pubmed: 21506647 pmcid: 3108434 doi: 10.1586/erv.10.174
Klinman, D. M., Sato, T. & Shimosato, T. Use of nanoparticles to deliver immunomodulatory oligonucleotides. WIREs Nanomed. Nanobiotechnol. 8, 631–637 (2016).
doi: 10.1002/wnan.1382
Schuller, V. J. et al. Cellular immunostimulation by CpG-sequence-coated DNA origami structures. ACS Nano 5, 9696–9702 (2011).
pubmed: 22092186 doi: 10.1021/nn203161y
Casaletto, J. B. & McClatchey, A. I. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat. Rev. Cancer 12, 387–400 (2012).
pubmed: 22622641 pmcid: 3767127 doi: 10.1038/nrc3277
Shaw, A. et al. Spatial control of membrane receptor function using ligand nanocalipers. Nat. Methods 11, 841–846 (2014).
pubmed: 24997862 doi: 10.1038/nmeth.3025
Kwon, P. S. et al. Designer DNA architecture offers precise and multivalent spatial pattern-recognition for viral sensing and inhibition. Nat. Chem. 12, 26–35 (2020).
pubmed: 31767992 doi: 10.1038/s41557-019-0369-8
Pulendran, B. & Ahmed, R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849–863 (2006).
pubmed: 16497593 doi: 10.1016/j.cell.2006.02.019
Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 520, 702–705 (2015).
pubmed: 25686612 doi: 10.1038/nature14138
Leleux, J. A., Pradhan, P. & Roy, K. Biophysical attributes of CpG presentation control TLR9 signaling to differentially polarize systemic immune responses. Cell Rep. 18, 700–710 (2017).
pubmed: 28099848 doi: 10.1016/j.celrep.2016.12.073
Schmidt, N. W. et al. Liquid-crystalline ordering of antimicrobial peptide-DNA complexes controls TLR9 activation. Nat. Mater. 14, 696–700 (2015).
pubmed: 26053762 doi: 10.1038/nmat4298
Lee, E. Y. et al. A review of immune amplification via ligand clustering by self-assembled liquid-crystalline DNA complexes. Adv. Colloid Interface Sci. 232, 17–24 (2016).
pubmed: 26956527 pmcid: 6519935 doi: 10.1016/j.cis.2016.02.003
Comberlato, A., Koga, M. M., Nussing, S., Parish, I. A. & Bastings, M. M. C. Spatially controlled activation of Toll-like receptor 9 with DNA-based nanomaterials. Nano Lett. 22, 2506–2513 (2022).
pubmed: 35266392 pmcid: 8949768 doi: 10.1021/acs.nanolett.2c00275
Du, R. R. et al. Innate immune stimulation using 3D wireframe DNA origami. ACS Nano 16, 20340–20352 (2022).
pubmed: 36459697 pmcid: 10144931 doi: 10.1021/acsnano.2c06275
Johansson, M., Denardo, D. G. & Coussens, L. M. Polarized immune responses differentially regulate cancer development. Immunol. Rev. 222, 145–154 (2008).
pubmed: 18363999 pmcid: 2494984 doi: 10.1111/j.1600-065X.2008.00600.x
Yew, N. S. et al. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol. Ther. 5, 731–738 (2002).
pubmed: 12027557 doi: 10.1006/mthe.2002.0598
Kumar, V. et al. DNA nanotechnology for cancer therapy. Theranostics 6, 710–725 (2016).
pubmed: 27022418 pmcid: 4805665 doi: 10.7150/thno.14203
Udomprasert, A. & Kangsamaksin, T. DNA origami applications in cancer therapy. Cancer Sci. 108, 1535–1543 (2017).
pubmed: 28574639 pmcid: 5543475 doi: 10.1111/cas.13290
Li, S. et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat. Biotechnol. 36, 258–264 (2018).
pubmed: 29431737 doi: 10.1038/nbt.4071
Liu, S. et al. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat. Mater. 20, 421–430 (2021).
pubmed: 32895504 doi: 10.1038/s41563-020-0793-6
Kern, N., Dong, R., Douglas, S. M., Vale, R. D. & Morrissey, M. A. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis. eLife 10, e68311 (2021).
pubmed: 34080973 pmcid: 8175083 doi: 10.7554/eLife.68311
Berger, R. M. L. et al. Nanoscale FasL organization on DNA origami to decipher apoptosis signal activation in cells. Small 17, e2101678 (2021).
pubmed: 34057291 doi: 10.1002/smll.202101678
Rothemund, P. W. Folding DNA to create nanoscale shapes and patterns. Nature 440, 297–302 (2006).
pubmed: 16541064 doi: 10.1038/nature04586
Douglas, S. M. et al. Self-assembly of DNA into nanoscale three-dimensional shapes. Nature 459, 414–418 (2009).
pubmed: 19458720 pmcid: 2688462 doi: 10.1038/nature08016
Liedl, T., Hogberg, B., Tytell, J., Ingber, D. E. & Shih, W. M. Self-assembly of three-dimensional prestressed tensegrity structures from DNA. Nat. Nanotechnol. 5, 520–524 (2010).
pubmed: 20562873 pmcid: 2898913 doi: 10.1038/nnano.2010.107
Shih, W. M. Exploiting weak interactions in DNA self-assembly. Science 347, 1417–1418 (2015).
pubmed: 25814568 doi: 10.1126/science.aaa9483
Dietz, H., Douglas, S. M. & Shih, W. M. Folding DNA into twisted and curved nanoscale shapes. Science 325, 725–730 (2009).
pubmed: 19661424 pmcid: 2737683 doi: 10.1126/science.1174251
Shen, H. et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117, 78–88 (2006).
pubmed: 16423043 pmcid: 1782199 doi: 10.1111/j.1365-2567.2005.02268.x
Min, Y. et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12, 877–882 (2017).
pubmed: 28650437 pmcid: 5587366 doi: 10.1038/nnano.2017.113
Chesson, C. B. & Zloza, A. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine 12, 2693–2706 (2017).
pubmed: 29098928 pmcid: 5704090 doi: 10.2217/nnm-2017-0254
Ponnuswamy, N. et al. Oligolysine-based coating protects DNA nanostructures from low-salt denaturation and nuclease degradation. Nat. Commun. 8, 15654 (2017).
pubmed: 28561045 pmcid: 5460023 doi: 10.1038/ncomms15654
Anastassacos, F. M., Zhao, Z., Zeng, Y. & Shih, W. M. Glutaraldehyde cross-linking of oligolysines coating DNA origami greatly reduces susceptibility to nuclease degradation. J. Am. Chem. Soc. 142, 3311–3315 (2020).
pubmed: 32011869 doi: 10.1021/jacs.9b11698
Lucas, C. R. et al. DNA origami nanostructures elicit dose-dependent immunogenicity and are nontoxic up to high doses in vivo. Small 18, e2108063 (2022).
pubmed: 35633287 pmcid: 9250639 doi: 10.1002/smll.202108063
Wamhoff, E. C. et al. Evaluation of nonmodified wireframe DNA origami for acute toxicity and biodistribution in mice. ACS Appl. Bio. Mater. 6, 1960–1969 (2023).
pubmed: 37040258 pmcid: 10189729 doi: 10.1021/acsabm.3c00155
Douglas, S. M. et al. Rapid prototyping of 3D DNA-origami shapes with caDNAno. Nucleic Acids Res. 37, 5001–5006 (2009).
pubmed: 19531737 pmcid: 2731887 doi: 10.1093/nar/gkp436
Njongmeta, L. M. et al. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals. Vaccine 30, 1624–1635 (2012).
pubmed: 22240344 doi: 10.1016/j.vaccine.2011.12.110
Lahoud, M. H. et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl Acad. Sci. USA 109, 16270–16275 (2012).
pubmed: 22988114 pmcid: 3479608 doi: 10.1073/pnas.1208796109
You, C. X. et al. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: evidence for IL-12 intracrine activity in DC. Oncoimmunology 1, 847–855 (2012).
pubmed: 23162752 pmcid: 3489740 doi: 10.4161/onci.20504
Heo, M. B., Kim, S. Y., Yun, W. S. & Lim, Y. T. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int J. Nanomed. 10, 5981–5992 (2015).
Scheuerpflug, A. et al. The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors. Cancer Immunol. Immunother. 70, 1343–1350 (2020).
pubmed: 33141285 pmcid: 8053142 doi: 10.1007/s00262-020-02767-6
Keestra, A. M., de Zoete, M. R., Bouwman, L. I. & van Putten, J. P. Chicken TLR21 is an innate CpG DNA receptor distinct from mammalian TLR9. J. Immunol. 185, 460–467 (2010).
pubmed: 20498358 doi: 10.4049/jimmunol.0901921
Oldenburg, M. et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 337, 1111–1115 (2012).
pubmed: 22821982 doi: 10.1126/science.1220363
Spies, B. et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171, 5908–5912 (2003).
pubmed: 14634101 doi: 10.4049/jimmunol.171.11.5908
Yu, D. et al. ‘Immunomers’–novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 30, 4460–4469 (2002).
pubmed: 12384593 pmcid: 137145 doi: 10.1093/nar/gkf582
Minari, J., Mochizuki, S. & Sakurai, K. Enhanced cytokine secretion owing to multiple CpG side chains of DNA duplex. Oligonucleotides 18, 337–344 (2008).
pubmed: 18844575 doi: 10.1089/oli.2008.0145
Smith, L. K. et al. Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity 48, 299–312 e295 (2018).
pubmed: 29396160 pmcid: 5935130 doi: 10.1016/j.immuni.2018.01.006
Li, A. W. et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat. Mater. 17, 528–534 (2018).
pubmed: 29507416 pmcid: 5970019 doi: 10.1038/s41563-018-0028-2
Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).
pubmed: 25901682 pmcid: 4838069 doi: 10.1038/nature14426
Toubi, E. & Shoenfeld, Y. Protective autoimmunity in cancer (review). Oncol. Rep. 17, 245–251 (2007).
pubmed: 17143505
Ke, Y., Voigt, N. V., Gothelf, K. V. & Shih, W. M. Multilayer DNA origami packed on hexagonal and hybrid lattices. J. Am. Chem. Soc. 134, 1770–1774 (2012).
pubmed: 22187940 pmcid: 3336742 doi: 10.1021/ja209719k
Douglas, S. M., Chou, J. J. & Shih, W. M. DNA-nanotube-induced alignment of membrane proteins for NMR structure determination. Proc. Natl Acad. Sci. USA 104, 6644–6648 (2007).
pubmed: 17404217 pmcid: 1871839 doi: 10.1073/pnas.0700930104
Hahn, J., Wickham, S. F., Shih, W. M. & Perrault, S. D. Addressing the instability of DNA nanostructures in tissue culture. ACS Nano 8, 8765–8775 (2014).
pubmed: 25136758 pmcid: 4174095 doi: 10.1021/nn503513p

Auteurs

Yang C Zeng (YC)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Olivia J Young (OJ)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Harvard-Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Christopher M Wintersinger (CM)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Frances M Anastassacos (FM)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

James I MacDonald (JI)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.

Giorgia Isinelli (G)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.
Department of Drug and Health Sciences, University of Catania, Catania, Italy.

Maxence O Dellacherie (MO)

Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.

Miguel Sobral (M)

Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.

Haiqing Bai (H)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.

Amanda R Graveline (AR)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.

Andyna Vernet (A)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.

Melinda Sanchez (M)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.

Kathleen Mulligan (K)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Youngjin Choi (Y)

Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.

Thomas C Ferrante (TC)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.

Derin B Keskin (DB)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Geoffrey G Fell (GG)

Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.

Donna Neuberg (D)

Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.

Catherine J Wu (CJ)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

David J Mooney (DJ)

Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.
Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.

Ick Chan Kwon (IC)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, Republic of Korea.

Ju Hee Ryu (JH)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. jhryu@kist.re.kr.
Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. jhryu@kist.re.kr.

William M Shih (WM)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. william_shih@dfci.harvard.edu.
Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA. william_shih@dfci.harvard.edu.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. william_shih@dfci.harvard.edu.

Classifications MeSH